• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. III

    2/9/22 4:34:30 PM ET
    $DNAC
    Get the next $DNAC alert in real time by email
    SC 13G 1 d252363dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Amendment No. __)*

    Under the Securities Exchange Act of 1934

     

     

    Social Capital Suvretta Holdings Corp. III

    (Name of Issuer)

    Class A Ordinary Shares, par value $0.0001 per share

    (Titles of Class of Securities)

    G8253W109

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out of a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      1    

      NAME OF REPORTING PERSON

     

      SCS Sponsor III LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Cayman Islands

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      6,860,000 (1)

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      6,860,000 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,860,000 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      21.5% (2)

    12  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    Reflects (i) 6,220,000 Class A ordinary shares of Social Capital Suvretta Holdings Corp. III (the “Company”), par value $0.0001 per share (“Class A Ordinary Shares”), issuable upon conversion of 6,220,000 Class B ordinary shares of the Company, par value $0.0001 per share (“Class B Ordinary Shares”). The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Company’s initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment and (ii) 640,000 additional Class A Ordinary Shares. SCS Sponsor III LLC (the “Sponsor”) is the record holder of the shares reported herein. The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA III, LLC (“SC SPAC Holdings”), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Aaron Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

    (2)

    The calculation assumes that there is a total of 31,860,000 Class A Ordinary Shares outstanding, which is the sum of (i) the 25,640,000 Class A Ordinary Shares outstanding as of November 15, 2021, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 (the “Report”), and (ii) the 6,220,000 Class A Ordinary Shares issuable upon conversion of the outstanding Class B Ordinary Shares held by the Sponsor.


      1    

      NAME OF REPORTING PERSON

     

      SC SPAC Holdings LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      6,860,000 (1)

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      6,860,000 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,860,000 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      21.5% (2)

    12  

      TYPE OF REPORTING PERSON

     

      OO

     

    (1)

    Reflects (i) 6,220,000 Class A Ordinary Shares, issuable upon conversion of 6,220,000 Class B Ordinary Shares. The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Company’s initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment and (ii) 640,000 additional Class A Ordinary Shares. The Sponsor is the record holder of the shares reported herein. The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings, which is controlled by Mr. Palihapitiya. Messrs. Mehta and Aaron Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

    (2)

    The calculation assumes that there is a total of 31,860,000 Class A Ordinary Shares outstanding, which is the sum of (i) the 25,640,000 Class A Ordinary Shares outstanding as of November 20, 2020, as reported in the Report, and (ii) the 6,220,000 Class A Ordinary Shares issuable upon conversion of the outstanding Class B Ordinary Shares held by the Sponsor.


      1    

      NAME OF REPORTING PERSON

     

      Chamath Palihapitiya

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      6,860,000 (1)

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      6,860,000 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,860,000 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      21.5% (2)

    12  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    Reflects (i) 6,220,000 Class A Ordinary Shares, issuable upon conversion of 6,220,000 Class B Ordinary Shares. The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Company’s initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment and (ii) 640,000 additional Class A Ordinary Shares. The Sponsor is the record holder of the shares reported herein. The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings, which is controlled by Mr. Palihapitiya. Messrs. Mehta and Aaron Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

    (2)

    The calculation assumes that there is a total of 31,860,000 Class A Ordinary Shares outstanding, which is the sum of (i) the 25,640,000 Class A Ordinary Shares outstanding as of November 20, 2020, as reported in the Report, and (ii) the 6,220,000 Class A Ordinary Shares issuable upon conversion of the outstanding Class B Ordinary Shares held by the Sponsor.


      1    

      NAME OF REPORTING PERSON

     

      Kishan Mehta

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      6,860,000 (1)

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      6,860,000 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,860,000 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      21.5% (2)

    12  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    Reflects (i) 6,220,000 Class A Ordinary Shares, issuable upon conversion of 6,220,000 Class B Ordinary Shares. The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Company’s initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment and (ii) 640,000 additional Class A Ordinary Shares. The Sponsor is the record holder of the shares reported herein. The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings, which is controlled by Mr. Palihapitiya. Messrs. Mehta and Aaron Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

    (2)

    The calculation assumes that there is a total of 31,860,000 Class A Ordinary Shares outstanding, which is the sum of (i) the 25,640,000 Class A Ordinary Shares outstanding as of November 20, 2020, as reported in the Report, and (ii) the 6,220,000 Class A Ordinary Shares issuable upon conversion of the outstanding Class B Ordinary Shares held by the Sponsor.


      1    

      NAME OF REPORTING PERSON

     

      Aaron Cowen

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      6,860,000 (1)

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      6,860,000 (1)

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      6,860,000 (1)

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐

     

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      21.5% (2)

    12  

      TYPE OF REPORTING PERSON

     

      IN

     

    (1)

    Reflects (i) 6,220,000 Class A Ordinary Shares, issuable upon conversion of 6,220,000 Class B Ordinary Shares. The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares at the time of the Company’s initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment and (ii) 640,000 additional Class A Ordinary Shares. The Sponsor is the record holder of the shares reported herein. The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings, which is controlled by Mr. Palihapitiya. Messrs. Mehta and Aaron Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.

    (2)

    The calculation assumes that there is a total of 31,860,000 Class A Ordinary Shares outstanding, which is the sum of (i) the 25,640,000 Class A Ordinary Shares outstanding as of November 20, 2020, as reported in the Report, and (ii) the 6,220,000 Class A Ordinary Shares issuable upon conversion of the outstanding Class B Ordinary Shares held by the Sponsor.


    Item 1(a).

    Name of Issuer:

    Social Capital Suvretta Holdings Corp. III

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    2850 W. Horizon Ridge Parkway, Suite 200, Henderson, NV 89052

     

    Item 2(a).

    Name of Person Filing:

    This statement is being filed jointly pursuant to §240.13d-1(k)(1) on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

      1.

    SCS Sponsor III LLC

     

      2.

    SC SPAC Holdings LLC (the successor by merger to ChaChaCha DNA III, LLC )

     

      3.

    Chamath Palihapitiya

     

      4.

    Kishan Mehta

     

      5.

    Aaron Cowen

     

    Item 2(b).

    Address of Principal Business Office or, if none, Residence:

    The principal business address of each of the Reporting Persons is as follows:

    c/o Social Capital Suvretta Holdings Corp. III, 2850 W. Horizon Ridge Parkway, Suite 200, Henderson, NV 89052

     

    Item 2(c).

    Citizenship:

    See responses to Item 4 on each cover page.

     

    Item 2(d).

    Titles of Classes of Securities:

    Class A Ordinary Shares, par value $0.0001 per share

     

    Item 2(e).

    CUSIP Number:

    The Class A Ordinary Shares CUSIP Number is G8253W109.

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).
    (b)    ☐    Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
    (c)    ☐    Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
    (d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)    ☐    Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).


    (f)    ☐    Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
    (g)    ☐    Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
    (h)    ☐    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)    ☐    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)    ☐    Non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
    (k)    ☐    Group in accordance with §240.13d-1(b)(1)(ii)(K).
    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________ .

     

    Item 4.

    Ownership

    (a) Amount beneficially owned:

    See responses to Item 9 on each cover page.

    (b) Percent of class:

    See responses to Item 11 on each cover page.

    (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote:

    See responses to Item 5 on each cover page.

    (ii) Shared power to vote or to direct the vote:

    See responses to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of:

    See responses to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of:

    See responses to Item 8 on each cover page.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    None.


    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10.

    Certification.

    Not Applicable.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 9, 2022

     

    SCS Sponsor III LLC
    By:  

    /s/ Chamath Palihapitiya

      Name: Chamath Palihapitiya
      Title: Chief Executive Officer
    SC SPAC Holdings LLC
    By: SC Master Holdings, LLC, its sole member
    By: Social Capital Group LLC, its sole member
    By:  

    /s/ Chamath Palihapitiya

      Name: Chamath Palihapitiya
      Title: Manager

    /s/ Chamath Palihapitiya

    Chamath Palihapitiya

    /s/ Kishan Mehta

    Kishan Mehta

    /s/ Aaron Cowen

    Aaron Cowen

    Exhibit Index

     

    Exhibit 1    Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.
    Get the next $DNAC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DNAC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DNAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Weger Mary

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    1/18/23 4:14:18 PM ET
    $DNAC

    SEC Form 4 filed by Weber Darin J.

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    1/18/23 4:13:35 PM ET
    $DNAC

    SEC Form 4 filed by Mckenzie Libbie Parker

    4 - PROKIDNEY CORP. (0001850270) (Issuer)

    1/18/23 4:12:58 PM ET
    $DNAC

    $DNAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III

    ProKidney Class A ordinary shares to begin trading on Nasdaq under the ticker symbol "PROK" on July 12, 2022 ProKidney receives total gross proceeds of approximately $597 million, expected to fund Phase 3 study of REACT™PIPE is led by a $125 million investment from Social Capital, with an additional $50 million from existing ProKidney investors, approximately $30 million from Suvretta Capital's Averill strategy and the remaining $370 million from institutional investors and family offices Proceeds will fund ongoing Phase 2 and 3 development program for ProKidney's lead cell therapy candidate, REACT™, accelerate manufacturing scale-out, and ultimately prepare for its global commercial launch

    7/12/22 8:00:00 AM ET
    $DNAC

    Social Capital Suvretta Holdings Corp. III Announces Reconvened Extraordinary General Meeting of Shareholders

    Social Capital Suvretta Holdings Corp. III ("SCS") today announced that it will reconvene the Extraordinary General Meeting of its shareholders to vote on the Business Combination Agreement, dated as of January 18, 2022, by and between SCS and ProKidney LP, a limited partnership organized under the laws of Ireland ("ProKidney"), acting through its general partner ProKidney GP Limited, a private limited company incorporated under the laws of Ireland, and the transactions contemplated thereby (the "Business Combination") on July 11, 2022 at 8:30 a.m., Eastern Time, physically at the offices of Wachtell, Lipton, Rosen & Katz located at 51 West 52nd Street, New York, New York 10019, and virtual

    7/8/22 7:36:00 PM ET
    $DNAC

    ProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease

    WINSTON-SALEM, N.C., June 23, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and the prevention of end-stage renal disease (ESRD) requiring dialysis or transplant, today published data from a patient study confirming the mechanistic action of its lead candidate REACT™ with cell marker analysis. "Renal Autologous Cell Therapy to Stabilize Function in Diabetes-Related Chronic Kidney Disease: Corroboration of Mechanistic Action with Cell Marker Analysis" by Joseph Stavas et. al. The paper, published in Kidney International Reports, describes observed improvements i

    6/23/22 8:00:00 AM ET
    $DNAC

    $DNAC
    SEC Filings

    View All

    SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. III

    424B3 - PROKIDNEY CORP. (0001850270) (Filer)

    1/20/23 6:52:24 AM ET
    $DNAC

    Social Capital Suvretta Holdings Corp. III filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - PROKIDNEY CORP. (0001850270) (Filer)

    1/19/23 4:18:53 PM ET
    $DNAC

    SEC Form 424B3 filed by Social Capital Suvretta Holdings Corp. III

    424B3 - PROKIDNEY CORP. (0001850270) (Filer)

    1/11/23 4:26:35 PM ET
    $DNAC

    $DNAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Social Capital Suvretta Holdings Corp. III

    SC 13G - PROKIDNEY CORP. (0001850270) (Subject)

    9/12/22 5:17:13 PM ET
    $DNAC

    SEC Form SC 13D filed by Social Capital Suvretta Holdings Corp. III

    SC 13D - PROKIDNEY CORP. (0001850270) (Subject)

    7/22/22 4:39:52 PM ET
    $DNAC

    SEC Form SC 13D filed by Social Capital Suvretta Holdings Corp. III

    SC 13D - PROKIDNEY CORP. (0001850270) (Subject)

    7/22/22 4:34:01 PM ET
    $DNAC

    $DNAC
    Financials

    Live finance-specific insights

    View All

    Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III

    ProKidney offers a first-of-its-kind, patented disease-modifying autologous cell therapy for treatment of chronic kidney disease ("CKD") Lead product candidate, REACT®, has potential to slow, stabilize, and even reverse decline in kidney function, delaying the onset of dialysis and potentially delivering significant cost savings to healthcare systems globally REACT® has received Regenerative Medicine Advanced Therapy ("RMAT") designation, as well as U.S. FDA and European Medicines Agency guidance, for its Phase 3 clinical program; Phase 3 trial launched in the United States on schedule in January 2022 Transaction values the combined company at an equity value of $2.64 billion post

    1/18/22 7:00:00 AM ET
    $DNAC
    $RPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DNAC
    Leadership Updates

    Live Leadership Updates

    View All

    ProKidney Appoints Libbie Parker McKenzie, MD, FASN as Chief Medical Officer

    WINSTON-SALEM, N.C., April 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on the treatment of chronic kidney disease (CKD) and prevention of both end-stage renal disease (ESRD) and the need for dialysis, today announced the appointment of Libbie Parker McKenzie, MD, FASN as Chief Medical Officer. "On behalf of our entire team, I am excited to welcome Libbie to ProKidney. Her deep clinical, pharmacovigilance and regulatory affairs expertise will be instrumental to our continued success as we work to advance the development of our lead program, REACT®," said Tim Bertram, Ph.D., Chief Executive Officer of ProKidney. "In a

    4/28/22 8:00:00 AM ET
    $DNAC

    ProKidney Appoints Todd C. Girolamo as General Counsel

    WINSTON-SALEM, N.C., March 28, 2022 (GLOBE NEWSWIRE) -- ProKidney LP (ProKidney), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (CKD) and prevention of end-stage renal disease (ESRD) and need for dialysis, today announced the appointment of Todd C. Girolamo as General Counsel. "We are thrilled to welcome Todd to the ProKidney team in such an important role," said Tim Bertram, Ph.D., Chief Executive Officer of ProKidney. "His experience as both an attorney and capital markets professional will be important to our future success, as we move closer to becoming a public company through our proposed merger with SCS. I look forward to wor

    3/28/22 8:00:00 AM ET
    $DNAC